GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
GO:000226220 | Oral cavity | OSCC | myeloid cell homeostasis | 98/7305 | 157/18723 | 2.29e-09 | 5.34e-08 | 98 |
GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
GO:000257310 | Oral cavity | OSCC | myeloid leukocyte differentiation | 119/7305 | 208/18723 | 7.29e-08 | 1.29e-06 | 119 |
GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
GO:0071887 | Oral cavity | OSCC | leukocyte apoptotic process | 60/7305 | 106/18723 | 1.78e-04 | 1.21e-03 | 60 |
GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
GO:009013018 | Oral cavity | OSCC | tissue migration | 176/7305 | 365/18723 | 1.92e-04 | 1.29e-03 | 176 |
GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:003514810 | Oral cavity | OSCC | tube formation | 78/7305 | 148/18723 | 4.82e-04 | 2.85e-03 | 78 |
GO:005067810 | Oral cavity | OSCC | regulation of epithelial cell proliferation | 180/7305 | 381/18723 | 5.88e-04 | 3.35e-03 | 180 |
GO:00302175 | Oral cavity | OSCC | T cell differentiation | 126/7305 | 257/18723 | 6.51e-04 | 3.66e-03 | 126 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0514615 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
hsa0421313 | Oral cavity | OSCC | Longevity regulating pathway - multiple species | 38/3704 | 62/8465 | 3.97e-03 | 9.86e-03 | 5.02e-03 | 38 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa04670113 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa046201 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa046621 | Oral cavity | OSCC | B cell receptor signaling pathway | 48/3704 | 84/8465 | 9.02e-03 | 2.01e-02 | 1.03e-02 | 48 |
hsa0401519 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
hsa0517146 | Oral cavity | EOLP | Coronavirus disease - COVID-19 | 108/1218 | 232/8465 | 8.08e-33 | 2.61e-30 | 1.54e-30 | 108 |
hsa0516744 | Oral cavity | EOLP | Kaposi sarcoma-associated herpesvirus infection | 68/1218 | 194/8465 | 2.59e-13 | 2.09e-11 | 1.24e-11 | 68 |
hsa0513245 | Oral cavity | EOLP | Salmonella infection | 78/1218 | 249/8465 | 3.66e-12 | 2.37e-10 | 1.40e-10 | 78 |
hsa0516943 | Oral cavity | EOLP | Epstein-Barr virus infection | 66/1218 | 202/8465 | 2.23e-11 | 1.20e-09 | 7.08e-10 | 66 |
hsa0516442 | Oral cavity | EOLP | Influenza A | 58/1218 | 171/8465 | 7.01e-11 | 3.23e-09 | 1.91e-09 | 58 |
hsa0541545 | Oral cavity | EOLP | Diabetic cardiomyopathy | 64/1218 | 203/8465 | 2.48e-10 | 1.00e-08 | 5.91e-09 | 64 |
hsa0516345 | Oral cavity | EOLP | Human cytomegalovirus infection | 68/1218 | 225/8465 | 5.29e-10 | 1.90e-08 | 1.12e-08 | 68 |
hsa0407141 | Oral cavity | EOLP | Sphingolipid signaling pathway | 44/1218 | 121/8465 | 1.19e-09 | 3.51e-08 | 2.07e-08 | 44 |
hsa0516041 | Oral cavity | EOLP | Hepatitis C | 52/1218 | 157/8465 | 1.79e-09 | 4.81e-08 | 2.84e-08 | 52 |
hsa0520845 | Oral cavity | EOLP | Chemical carcinogenesis - reactive oxygen species | 66/1218 | 223/8465 | 2.50e-09 | 5.76e-08 | 3.40e-08 | 66 |
hsa0493245 | Oral cavity | EOLP | Non-alcoholic fatty liver disease | 51/1218 | 155/8465 | 3.32e-09 | 6.74e-08 | 3.98e-08 | 51 |
hsa0517043 | Oral cavity | EOLP | Human immunodeficiency virus 1 infection | 63/1218 | 212/8465 | 4.85e-09 | 8.71e-08 | 5.14e-08 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3CD | SNV | Missense_Mutation | | c.20G>A | p.Cys7Tyr | p.C7Y | O00329 | protein_coding | tolerated_low_confidence(0.34) | benign(0.197) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
PIK3CD | SNV | Missense_Mutation | novel | c.3028N>A | p.Glu1010Lys | p.E1010K | O00329 | protein_coding | deleterious(0.04) | benign(0.443) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PIK3CD | SNV | Missense_Mutation | | c.2780G>A | p.Arg927His | p.R927H | O00329 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PIK3CD | SNV | Missense_Mutation | | c.975C>G | p.Ile325Met | p.I325M | O00329 | protein_coding | deleterious(0.02) | possibly_damaging(0.619) | TCGA-D8-A27F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
PIK3CD | SNV | Missense_Mutation | novel | c.1895N>C | p.Phe632Ser | p.F632S | O00329 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A243-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
PIK3CD | insertion | In_Frame_Ins | novel | c.1370_1371insCCT | p.Gly457_Thr458insLeu | p.G457_T458insL | O00329 | protein_coding | | | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CD | insertion | Frame_Shift_Ins | novel | c.1372_1373insGAGGAAAGAGGAAAAAGCGG | p.Thr458ArgfsTer96 | p.T458Rfs*96 | O00329 | protein_coding | | | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CD | SNV | Missense_Mutation | | c.2617N>A | p.Glu873Lys | p.E873K | O00329 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
PIK3CD | SNV | Missense_Mutation | rs369126260 | c.1993N>A | p.Gly665Ser | p.G665S | O00329 | protein_coding | tolerated(0.06) | possibly_damaging(0.694) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
PIK3CD | SNV | Missense_Mutation | | c.262C>T | p.Arg88Cys | p.R88C | O00329 | protein_coding | deleterious(0.03) | probably_damaging(0.969) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | NVP-BEZ242 | | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 223366125 | TASELISIB | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565579 | APITOLISIB | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565693 | | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | PWT33597 | | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | IDELALISIB | IDELALISIB | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565922 | | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 310264749 | SERABELISIB | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565648 | | |
5293 | PIK3CD | KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565924 | | |